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Since 1996, there have been at least six human norovirus pandemics. All of the pandemic strains are genetically related, segregat-
ing in the genogroup II, genotype 4 (GII.4) cluster within the Norovirus genus. Evidence indicates that these strains are closely
related but antigenically distinct, supporting immune-driven viral evolution. Thus, norovirus vaccines will likely require peri-
odic reformulation to protect from newly emergent strains. A major obstacle is that the reservoir of emergent strains is un-
known. Noroviruses display tight species specificity and there is no evidence supporting zoonotic transmission, so an animal
reservoir is considered unlikely. Moreover, available data indicate minimal viral diversity in most natural human infections. In
this Gem, we discuss the widely speculated idea that chronically infected immunocompromised individuals are norovirus reser-
voirs and provide a rationale for the theory that elderly and malnourished hosts may also represent norovirus reservoirs.
Human noroviruses are positive-sense RNA viruses with7.5-kb genomes divided into three open reading frames
(ORFs). ORF1 encodes a large polyprotein that is cleaved into six
mature nonstructural proteins, ORF2 encodes a major capsid pro-
tein called VP1 that can self-assemble into virus-like particles
(VLPs), and ORF3 encodes a minor structural protein called VP2.
Human noroviruses are a major cause of gastroenteritis outbreaks
across the globe and are the leading cause of both severe childhood
diarrhea and food-borne disease outbreaks in the United States.
Although norovirus infections typically result in acute and self-
limiting gastroenteritis, young children, the elderly, and immuno-
compromised patients are vulnerable to more severe and pro-
longed infections. In particular, immunocompromised and
transplant patients can be chronically infected with a human no-
rovirus (1). In developing countries, they are likely an even more
substantial cause of severe disease, as supported by an estimate
that they cause over one million clinic visits and 200,000 deaths in
young children annually in this setting (2). Although a recent
global enteric multicenter study (GEMS) questioned whether hu-
man noroviruses are indeed a significant cause of disease in devel-
oping nations (3), it is important to recognize that the viral detec-
tion assay used in that study was extremely outdated and much
less sensitive than well-established quantitative and broadly reac-
tive reverse transcription-PCR assays in common use today; thus,
the GEMS very likely grossly underestimated the norovirus dis-
ease burden. This argument is strongly supported by innumerable
reports of norovirus detection in 20% of children hospitalized
with diarrhea from all parts of the world. For example, Ahmed et
al. recently documented an 18% norovirus prevalence in 187,336
patients with acute gastroenteritis when analyzing 175 separate
and geographically diverse studies (4). Development of effective
human norovirus vaccines would thus prevent significant mor-
bidity and mortality worldwide. However, noroviruses are ex-
tremely genetically diverse, significantly complicating vaccination
strategies. Moreover, new pandemic strains emerge every 2 to 4
years that appear to be antigenically distinct from previously cir-
culating strains. It is thus likely that periodic vaccine reformula-
tions will be required to protect from emergent human norovirus
strains, similar to current influenza virus vaccination strategies.
Unfortunately, the reservoir(s) of human noroviruses and the
mechanisms regulating intra-and interhost norovirus evolution-
ary patterns remain ill-defined. This information is critical for the
design of effective vaccines and to enhance our ability to predict
the emergence of new strains on the basis of the efficiency of viral
adaptability under different conditions. In this review, we will
provide an in-depth analysis of the current view of norovirus res-
ervoirs.
EMERGENCE OF PANDEMIC NOROVIRUS STRAINS
Human norovirus pandemics occurred in 1996-1997, 2002, 2004,
2006, 2009, and 2012. All six pandemics were caused by the emer-
gence and rapid global spread of viral variants segregating within
the genogroup II, genotype 4 (GII.4) human norovirus cluster.
Most recently, the GII.4 Sydney strain caused a sharp spike in
outbreaks globally during the 2012-2013 winter season. On the
basis of the epochal pattern of evolution among these six pan-
demic strains and their high level of genetic relatedness, it is highly
likely that population level immunity curbs pandemics after one
or two seasons and immune escape mutations result in the emer-
gence of successive pandemic strains. Indeed, available evidence
demonstrates that GII.4 pandemic strains are not efficiently rec-
ognized by antibodies generated to previously circulating strains
(e.g., see reference 5). Specifically, using time-ordered polyclonal
and human monoclonal antibodies, time-ordered VLPs, and a
surrogate assay for neutralizing antibody detection, multiple stud-
ies have shown that contemporary strains evolve mutations that
attenuate the ability of ancestral strain immune sera to block bind-
ing to histo-blood group antigen (HBGA) carbohydrates. In fact,
three highly variable antibody blockade epitopes exist on the sur-
face of the GII.4 virus particle which change during successive
waves of pandemic viruses (6). Epitope mapping was performed
by using bioinformatic approaches to identify and cluster rapidly
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evolving amino acid residues on the surface of VLPs and then
exchanging these regions between VLPs. By using functional as-
says, precise mapping of key residues that drive antigenic change
in response to human and mouse antibody binding and blockade
then provided direct evidence of antigenic variation during GII.4
evolution. Of the epitopes identified, variation in the A epitope
domain most closely maps with new strain emergence and pan-
demic disease outbreaks.
Understanding the evolutionary pressures regulating intra-
and interhost norovirus diversity should inform the processes un-
derlying pandemic strain emergence. Viral diversity can enhance
the adaptability of a viral swarm by increasing the probability of
phenotypically distinct variants. These could include antigenic
variants that are not efficiently recognized by immunity to previ-
ously circulating strains and variants with increased virulence. Di-
versity is influenced by viral factors such as the inherent muta-
tional rate of the viral replicative enzyme, the replication rate of
the virus, and host factors, with the magnitude and nature of the
immune response playing a dominant role. The norovirus RNA-
dependent RNA polymerase (RdRp) has a high error rate, with
available evidence indicating that the RdRp of GII.4 human noro-
virus strains has a higher rate of mutation than other genotypes
(7). In spite of this, available data—admittedly limited in scope—
indicate that the complexity of the norovirus quasispecies in in-
fected individuals with a normal immune system is quite low. For
example, Bull et al. observed only one single nucleotide polymor-
phism (SNP) in the ORF2/partial ORF3 genes over a 9-day period
of infection in a healthy subject (8); and Vega et al. identified no
nucleotide differences from a published virus sequence among 10
VP1 clones from an immunocompetent subject (9). While future
studies using deep sequencing of the entire viral genome from
larger cohorts are necessary to more accurately determine in vivo
viral evolution rates, early data do support surprisingly limited
viral diversity in immunocompetent individuals. Considering
this, where do pandemic strains arise? Although noroviruses have
been identified in a diverse range of animals, there is no evidence
of zoonotic transmission (10), so it is reasonable to presume that
variant viruses arise within the human population.
EVIDENCE FOR IMMUNOCOMPROMISED HOSTS AS
NOROVIRUS RESERVOIRS
Immunocompromised and transplant patients can develop
chronic norovirus infections that last months and even years (1).
Because of the extended nature of these infections and the reduced
immune pressure restricting viral mutation, many groups have
speculated that the immunocompromised host represents a noro-
virus reservoir. Indeed, multiple studies have investigated longi-
tudinal human norovirus diversity in chronically infected immu-
nocompromised patients, and a high degree of viral sequence
heterogeneity was observed in each case (8, 9, 11–15). For exam-
ple, in the same study detecting one SNP in a healthy host over 9
days of infection, 18 SNPs were detected over 288 days of infection
in an immunocompromised subject (8). Furthermore, the quasi-
species appeared to be quite complex in the immunocompro-
mised host, in striking contrast to the homogeneous viral popula-
tion observed in four healthy subjects (8). However, a critical
distinction between viral diversity and viral evolution must be
recognized—if immunocompromised individuals are unable to
mount a robust antiviral antibody response, it is unlikely that viral
mutations resulting in immune escape will become dominant in
the viral quasispecies. The phylodynamic framework for RNA vi-
rus evolution proposed by Grenfell et al., in fact, argues that inter-
mediate levels of immunity should result in maximal intrahost
viral adaptation (16) (Fig. 1). This framework is based on the idea
that a robust immune response in immunocompetent individuals
will fully suppress viral replication, thereby restricting the produc-
tion of fitter viruses; an absence of immunity in severely immu-
nocompromised hosts will result in a complex quasispecies but no
pressure to select for fitter variants; while a weak immune re-
sponse will fail to completely shut down viral replication while
simultaneously providing some selective pressure for escape mu-
tants. There is support for this model in relation to human noro-
virus evolution; Siebenga et al. revealed that the number of VP1
amino acid changes over time was higher in patients with inter-
mediate immunocompromise than in more severely immuno-
compromised patients (15). Collective preliminary data thus sug-
gest that human norovirus adaptation is suppressed in healthy
people, presumably by a robust immune response; occurs maxi-
mally in hosts with intermediate levels of immunity, where selec-
tive pressure is applied by the immune response but it is not robust
enough to completely clear infection; and is minimal in severely
immunocompromised individuals who fail to generate selective
pressure.
To directly test whether increased viral quasispecies complex-
ity translates into clinically relevant phenotypic variability, it is
necessary to examine whether viral mutations arising in immuno-
compromised hosts provide fitness benefits (e.g., increased viral
replication, antigenic variability, enhanced virulence). However,
until very recently human noroviruses could not be cultured in the
laboratory and no efficient reverse genetic system was available,
precluding direct testing of the effects of viral mutations on anti-
FIG 1 Model of RNA virus evolution. The current framework for the adapta-
tion rate of fast-evolving RNA viruses like noroviruses (black line) is the net
result of the complexity of the viral quasispecies resulting from the inherent
error rate of the RdRp (red line), the strength of the selective pressures applied
to this viral population by the host (blue line), and the replication rate of the
virus (not accounted for in this model). In this model, immunocompromised
hosts (point 1) have a complex quasispecies because of the high error rate of
the RdRp but low adaptation because of reduced selective pressure, healthy
hosts (point 3) develop a robust immune response that limits the development
of a complex quasispecies, and hosts with intermediate immunity (point 2)
display the highest adaptation rate because of the development of weak selec-
tive pressure—this pressure is insufficient to completely control viral replica-
tion, so a complex quasispecies develops, but it is sufficient to drive the evolu-
tion of the virus. Adapted from reference 16.
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body binding/neutralization and viral replication efficiency. In
the absence of these basic virological tools, researchers have relied
on the ability of the norovirus VP1 protein to self-assemble into
VLPs, which facilitates genetic testing of mutations arising in this
viral protein; and a surrogate neutralization assay whereby anti-
bodies are tested for the ability to prevent VLP binding to an
HBGA attachment factor. One recent study by Debbink et al. uti-
lized these tools to probe the critical question of whether increased
quasispecies complexity in immunocompromised hosts is indica-
tive of the presence of phenotypically distinct viral variants (17).
Specifically, VLPs were synthesized from ORF2 genes containing
either the GII.4-2006 pandemic strain or the consensus sequences
from two temporal samples of a chronically infected subject 302
days apart. These VLPs displayed differences in carbohydrate
binding, antibody reactivity, and antibody blockade activity, pro-
viding support for the emergence of phenotypically distinct viral
variants in a chronically infected immunocompromised host. Fu-
ture phenotypic analyses of viral mutations arising in immuno-
compromised hosts will be greatly facilitated by the recent devel-
opment of a human norovirus cell culture system (18) and a
helper-free human norovirus reverse genetics system (19). More-
over, it will be important to consider whether elderly individuals
can act as viral reservoirs since they are immunosuppressed and
can have more severe and prolonged norovirus infections than
younger adults.
EVIDENCE FOR NUTRITIONAL REGULATION OF NOROVIRUS
EVOLUTION
Considering the premise that viral evolution occurs most readily
under conditions of weak immunity (16), we have begun to test
whether malnourished hosts support higher levels of norovirus
evolution than their healthy counterparts and could thus repre-
sent a potential viral reservoir. This hypothesis is based on the
well-established knowledge that malnourished people mount
suboptimal immune responses and are highly susceptible to severe
and prolonged viral infections. A murine model of norovirus in-
fection was used to test this hypothesis because it allowed us to
examine the impact of malnutrition on viral evolution in the ab-
sence of confounding host and environmental variability. Indeed,
mice fed a diet low in protein (reflecting a common form of mal-
nutrition observed in children in developing nations referred to as
protein energy malnutrition) displayed greater viral diversity, as
indicated by a significantly higher number of nonsynonymous
substitutions in the VP1 protein, than healthy mice at 50 days
postinfection (20). In particular, there was a significantly higher
number of virion surface-exposed mutations in the malnourished
mice than in their healthy counterparts. This increased viral diver-
sity correlated with increased severity of infection, reduced viral
clearance, and a substantially reduced mucosal antiviral antibody
response in spite of increased virus titers. Considering the likely
scope of norovirus infections in malnourished people each year
(2), their potential as reservoirs of phenotypically distinct norovi-
rus strains warrants further study.
Although we have focused our discussion on intrahost norovi-
rus evolution, pandemic strain emergence is also likely shaped by
population phylodynamics. For example, neutral viral evolution
occurring during widespread outbreaks combined with positive
selection of new antigenic variants could explain GII.4 evolution-
ary patterns. Another factor known to contribute to norovirus
evolution is the ability of the viral genome to recombine, with a
recombination hot spot identified at the ORF1-ORF2 border.
PERSPECTIVES
Although the epidemiological pattern of human norovirus pan-
demics is very similar to that of influenza viruses, a major distinc-
tion is the apparent absence of animal reservoirs of noroviruses
that support viral mixing and zoonotic transmission. Thus, a crit-
ical goal in tackling future norovirus vaccine design is identifying
the reservoir of emergent pandemic strains. It has been widely
speculated that chronically infected immunocompromised sub-
jects may represent a reservoir of emergent strains. This idea stems
from the well-supported observation that the viral quasispecies in
immunocompromised hosts are complex, in striking contrast to
the very stable viral populations in healthy hosts. We propose in
this Gem that the degree of immunocompromise in individual
patients will play a major role in determining the extent of viral
evolution (in contrast to viral diversity) that arises. We also pro-
pose that elderly and malnourished hosts represent other likely
viral reservoirs because of their suboptimal— but not absent—
immune response to viral infections; this idea is supported by
recent work with the murine norovirus model system. Unequiv-
ocal demonstration of the emergence of novel viral variants re-
quires phenotypic testing of adaptive mutations. Unfortunately,
limitations in experimental human norovirus systems have pre-
cluded an in-depth analysis of whether viral diversity in the setting
of immunocompromise translates to phenotypic variability. One
recent study did demonstrate antigenic variability arising in a sin-
gle immunocompromised host by using existing research tools,
warranting continued study of a larger number of subjects with
defined but variable levels of immunocompromise and malnutri-
tion. Moreover, recent advances in human norovirus research
tools, including a cell culture system and an efficient reverse ge-
netics system, should greatly advance the ability of the field to test
for phenotypic consequences associated with viral genetic
changes.
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